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 This paper explores a total of six research studies and will contain a literature review and 
proposal for further study regarding the effectiveness of the ketogenic diet as an adjuvant cancer 
therapy. Each study addresses a variety of different factors involved in KD implementation, 
ranging from effects on body composition and lipid profiles, to self-proclaimed quality of life, to 
tumor expression and progression under a KD regime. Ultimately, each were divided into three 
separate categories depending on the aspects of research that were covered. Two studies, by 
Hagihara et.al and Jansen and Walach respectively, discuss the potential benefits of KD in cancer 
patients, while two additional studies by Sremanokova et.al and Klement et.al address concerns 
regarding the implementation of KD in cancer populations. The final category and studies by 
Yang et.al and Erickson et.al claim a lack of significance in the use of KD in clinical practice, 
and examine why this is the case. The major findings and limitations of each study will be 
discussed in detail, alongside theme comparisons between studies. Based on the findings 
discussed, the new research question in the proposal for further study will address the anti-tumor 
effects of KD on glioblastoma specifically. The study will be a longitudinal mixed method 
design and will only involve participants diagnosed with glioblastomas. The data obtained 
through conducted interviews and surveys will be analyzed through audio recordings, written 
assessment scales, and questionnaires completed by participants. Additional lab work will be 
done for the statistical analysis portion and will observe changes in blood ketone levels, TKTL1 
expression, and cfDNA blood levels respectively. The final portion will discuss the consensus 
between both the literature review and proposal for further study, which is that KD shows 
promise as an adjuvant therapy in cancer populations.   
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Introduction: The Ketogenic Diet and Cancer Therapy 
While many leaps and bounds have been made in the study of cancer and its subsequent 
treatment, there is still room for growth in the use of adjuvant therapies to increase efficacy and 
quality of life in patients. “In recent years, attention was drawn to the fact that diet-associated 
factors may be involved in the development and progression of cancer” (Jansen & Walach, 2016, 
para. 2). That said, one such avenue that shows promise is the ketogenic diet, a high-fat low-
carbohydrate diet with increased protein consumption. The traditional ketogenic diet consists of 
a 4:1 ratio, which “delivers 90% of its calories from fat, 8% from protein and only 2% from 
carbohydrate” (National Center for Biotechnology Information, 2020, para. 9). Its practice has 
already been utilized as a second-line treatment for epilepsy in pediatric populations with much 
success. 
However, there is debate in the scientific community regarding whether or not the 
implementation of KD is as effective in cancer populations as it is in epileptic populations. Many 
speculate that KD may provide an antitumor effect by creating an unfavorable environment for 
cancer cells through a decrease in carbohydrate consumption. Such cells thrive on the glucose 
contained in carbohydrates, and it is through this diet, alongside the use of standard cancer 
therapies such as chemo and radiotherapy, that tumor progression can be halted, increased 
tolerability to treatment, and improved quality of life for patients may be achieved. However, 
according to the National Center for Biotechnology Information (2020), “to further elucidate the 
mechanisms of the ketogenic diet as a therapy and evaluate its application in clinical practice, 
more molecular studies as well as uniformly controlled clinical trials are needed” (para. 3). The 
following thesis, including a comprehensive review of the research literature and proposal for 
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further study, is a way to provide additional insight into this area of interest, and to answer the 
question of how effective the ketogenic diet is for adjuvant cancer therapy in clinical practice. 
Literature Review 
The Dominican University databases were utilized in the search for information 
regarding the ketogenic diet and cancer treatment. All search terms were variants of these two 
descriptions, and the research was confined to the following databases: Iceberg, CINAHL, 
PubMed, and Cochrane. Six studies were used in total, and only ones that involved human trials 
and introduced KD as an adjuvant therapy were taken into consideration. Due to the versatility of 
KD effects on different cancer types, studies that only reviewed a single form of cancer were 
excluded from this review, but measures were taken to ensure that these studies provided 
evidence related to their respective cancer markers and how they correlate with KD. All studies 
involved were limited to either systematic reviews, randomized controlled trials, or meta-
analyses.  
Each study was divided into three separate categories. In the first category, the sources 
showed promising evidence for KD as a beneficial form of therapy alongside other cancer 
treatments. However, despite their many benefits, they also discuss how these results are not 
enough to support the practical use of KD in clinical settings. They merely serve as avenues for 
further study and provide valid evidence to support the idea that KD should continue to be 
researched as an alternative form of cancer therapy. The second category included sources that 
addressed the concerns regarding the use of KD on cancer populations and the potential barriers 
that need to be considered before it can be clinically implemented. The final source category 
described how KD implementation yielded inconclusive evidence and should not be considered 
for clinical practice.  
7 
Study Findings Show Promise in Primary Care 
Hagihara et.al (2020) came together to conduct a study that evaluated the effectiveness of 
a new ketogenic diet regimen in patients with different types of stage IV cancer. The purpose 
was to determine whether KD could be used as a supportive therapy in clinical practice and to 
establish the extent that carbohydrate restrictions could be implemented in those with cancer. 
Fifty-five participants gave their consent in total, with data only being taken from 37 partaking in 
KD for three months or more. Major findings of the study yielded that the effects of KD differ 
depending on the cancer type, but across their respective lab markers and lipid profiles, KD in 
combination with chemotherapy or radiation was correlated with a decrease in tumor and 
metastases size. Paired with these standard cancer therapies, Hagihara et.al (2020) stated that 
“The present ketogenic diet regimen had better tolerability, with less nausea, fatigue, and 
constipation, and it induced stable adherence” (Discussion section, para. 5). In addition, “results 
suggest that weight loss is not a toxic effect of the ketogenic diet” (Discussion section, 2020, 
para. 5) despite weight loss risk in cancer patients. Many maintained adequate nutrition and 
muscle mass despite the change in diet. 
These results indicate that adverse symptoms and body composition risks associated with 
the implementation of KD in cancer populations are not a primary concern. Overall, KD seems 
to have a positive effect on cancer patient’s long-term prognoses and may contribute to long-
term survival with controlled use. However, some results may be controversial due to limitations 
in dietary restriction. If dietary restriction is insufficient, it may alter patient lab results and leave 
anti-tumor effects unclear. In summary, should future modifications and additional research be 
pursued, KD offers hope as a promising avenue for support therapy in cancer populations. 
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An additional study by Jansen and Walach (2016) wanted to evaluate whether the levels 
of TKTL1, a novel marker of tumor cell glycolysis, are affected by a ketogenic diet, and whether 
adherence to KD is associated with a better prognosis in patients with cancer. Seventy-two 
subjects diagnosed with any form of cancer since January 2001 were included in the study. 
According to Jansen and Walach (2016), “Results obtained suggest that there is a positive link 
between the expression of TKTL1 and cancer progression, and a negative link between ketogenic 
diet and TKTL1 expression” (Discussion section, para. 6). These results indicate that the 
expression of TKTL1 is associated with tumor progression. However, when KD was introduced, 
TKTL1 expression was observed to be halted. Jansen and Walach (2016) claim that “reduced 
expression levels of TKTL1, which are a negative predictor of cancer progression, may reflect 
the effect of a ketogenic diet” (Discussion section, para. 6). Noting these changes in lab values, 
Jansen and Walach surmounted that it may be beneficial to advise individuals with cancer to 
adopt KD due to the altered expression of TKTL1. 
However, despite altered TKTL1 values, patients are still at risk for recurrences or 
metastases. Additionally, not all individuals maintained a consistent regime while on KD, which 
may have skewed overall results. 
Concerns Regarding KD for Cancer Populations 
While benefits of the ketogenic diet are certainly present in study findings, there is still 
skepticism surrounding the safety of its use for individuals with cancer. Klement et.al (2020) 
were concerned with the skepticism regarding lack of adequate clinical research supporting the 
effectiveness of the ketogenic diet as a cancer therapy. They claim that a “lack of studies 
occupying higher levels in typical ‘evidence hierarchies’ has been emphasized by some 
authors...discouraging the clinical application of KDs” (Klement, p. 5, 2020). This is known as 
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“methodological skepticism” and serves as a strong barrier towards confidence in KD efficacy. 
In an effort to address such concerns, the subsequent study was executed and focused on research 
that had implemented KD in medical oncological treatments. Despite previous concerns, data 
found that there are large beneficial effects of KD on body composition in both overweight and 
frail populations, as well as those at risk for excessive weight loss due to cancer or while 
undergoing cancer treatment. Additional evidence by Klement et.al (2020) suggests that KD 
“acts synergistically with radiotherapy, chemotherapy, and other therapies” (p. 9), as well as 
“[deprives] cancer cells of important anti-oxidative substrates'' (p. 9) to inhibit growth. The 
evidence supporting KDs as a supportive cancer therapy is steadily growing and suggests several 
benefits in clinical practice.  
Sremanokova et.al’s (2018) study was concerned with the nutritional aspect of KD and 
aimed to determine its effects on cancer patient’s nutritional status, as they stated that “KD has 
the potential to influence many physiological processes…[incurring] weight loss, muscle wasting 
and severe inflammation, which can lead to morbidity and poorer quality of life” (Introduction 
section, para. 4). A total of 102 participants ranging 34 to 87 years old were included in the 
study, all with a variety of different cancer types at different stages. Based on analysis of 
anthropometry, lipid profiles, tumor effects, and adverse events, the study found that KD does 
not cause life-threatening events and may even be feasible as a therapy with the right parameters. 
However, Sremanokova et.al (2018) claim that KD “adherence is low and possibly linked to a 
limitation in diet delivery, as well as a lack of monitoring and follow-up” (Conclusion section, 
para. 1). This indicates that while no life-threatening events were observed, lack of proper KD 
implementation may have contributed to these results. Other barriers such as lack of ketone 
measurements, which is a staple value in evaluating ketogenic effectiveness, short KD duration, 
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and small sample sizes, were also noted, which made it difficult to reach a valid conclusion. 
Sremanokova et.al deduced that while there are sound theoretical bases for KD suppressing 
tumor growth across different cancer types, strong conclusive evidence in clinical practice is 
lacking. 
No Statistical Significance 
The following studies were some of the few that claimed there was inadequate evidence 
to support the beneficial effects of the ketogenic diet on antitumor therapy. In Yang et.al’s 
(2021) study, rigorous comparison of different factors such as lipid profiles, tumor markers, level 
of satisfaction, and adverse effects found that “most evidence did not have any statistical 
significance and therefore the effects of LCKDs as an adjuvant therapy on cancer management 
was inconclusive” (Discussion section, para. 5). Yang et.al bring up a very important point in the 
study’s discussion portion, claiming that it is difficult to accurately draw comparisons between 
studies because each follows its own set of protocols and are within different parameters. Data 
collection in one study may include qualitative aspects that give more depth to the patient’s 
experience while others may choose to focus on statistical values seen in laboratory results or 
profiles. This lack of consistency in data, in the words of Yang et.al (2021), makes it “difficult to 
obtain an accurate conclusion to dictate the ketogenic diet as adjuvant therapy for cancer” 
(Discussion section, para. 10). As such, it cannot be exclusively proven whether KD is effective 
or ineffective as an adjuvant form of cancer therapy.  
Erickson et.al (2017) take a similar approach to this claim, and ultimately they come to 
the same conclusion as Yang:  “...evidence on [ketogenic] benefits regarding tumor development 
and progression as well as reduction in side effects of cancer therapy is missing” (p. 11). Similar 
to the previous study, their goal was to assess the effectiveness of a KD regime, specifically in 
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regards to weight maintenance, and acquire structure to determine how to implement this regime 
best in cancer patients. However, after the analysis of results related to tumor progression, 
regime duration, quality of life, and body composition, ultimately no statistically significant 
evidence could be found. Erickson et.al (2017) claim that “The studies are limited by their 
sample sizes and lack in homogeneity of type, location and cancer stage, and thus, results cannot 
be compared” (Results section, p. 2, 2017). In addition to this, “studies in the area of cancer lack 
consistency and do not utilize clearly comparable and consistent standardized dietary protocols” 
(Results section, p. 2, 2017).  Validity and reliability of results are unable to be achieved in the 
case of inconsistent study implementation. For this reason, interpretation of the data presented 
for KD effectiveness in cancer therapy cannot be regarded as accurate. As a result, Erickson et.al 
(2017) suggest that “More robust and consistent clinical evidence investigating comparable 
patient groups with comparable methodology, dietary protocols and consistent results are 
warranted before the KD can be recommended for any single cancer diagnosis or as an adjunct 
therapy” (Conclusion section, p.1) 
Discussion of the Literature 
While there have certainly been benefits observed in the use of the ketogenic diet 
alongside cancer therapy, such as slowed tumor progression and maintenance of healthy body 
composition, concrete and measurable evidence of said benefits are still largely inconclusive. 
Many of these studies had limitations in their research that were not addressed or could not be 
overcome. A common theme in such limitations mainly had to do with small sample sizes, lack 
of homogeneity between cancer types, inconsistent diet implementation, and unequal study 
parameters. Smaller sample sizes indicate an inaccurate representation of the larger cancer 
population, and with each study conducting their research with different sets of parameters, 
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results indicate an unreliable portrayal of the effects of KD as an adjuvant cancer therapy. In 
addition, the purpose of including a variety of different cancers was to determine how KD affects 
each one individually. However, the broader the range of conditions to identify and research, the 
more difficult it becomes to accurately compare data. This lack of reliability and validity 
between studies creates a skewed cesspool of results, and despite the benefits observed, they are 
not enough to place sure confidence in clinical practice.  
However, this does not mean that KDs lack promise in the potential to strengthen cancer 
therapy. If there is one thing that the studies share in common, it is the need for further research 
into this avenue of treatment, as many of them have claimed themselves. More controlled trials 
are necessary before KD can seriously be considered as an adjuvant therapy, and with new 
research being presented every year, the hope is that these future studies will address concerns 
that their predecessors have identified before them. Overall, while the research into KD is still in 
its infant stages among the cancer population, the aforementioned studies recognize that it is a 
valid adjuvant therapy to be pursued further, so long as limitations are addressed and attempted 
to be corrected. 
Theoretical Framework 
 As briefly mentioned, a common theme across the studies was the participants’ inability 
to utilize the ketogenic diet to completion. Many stopped KD a quarter or midway through, and 
others, despite using KD to completion, were not consistent with their diet’s implementation. 
While this may have skewed data and results, it is important to understand that, especially in the 
case of cancer treatment, the patient always has the final say when it comes to decisions of care. 
According to Orem’s Self-Care Deficit Nursing Theory, “People are distinct individuals” and 
“should be self-reliant, and responsible for their care, as well as others in their family who need 
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care” (Nursing Theory, n.d., p. 3). If there are deficits in a person’s ability to administer self-
care, that is when nursing intervention must be implemented. This creates an interpersonal 
relationship between nurse and patient, where the nurse communicates accurate and reliable 
information regarding a patient’s condition and treatments, and the patient is enabled to make 
well-educated decisions about administration of self-care. 
In the case of cancer populations, medical and therapeutic interventions will likely be 
implemented to better manage their conditions, no matter the cancer type. That being said, the 
patient will always be the final decision maker when it comes to actual implementation of these 
interventions. The nurse is responsible for “acting for and doing for others; guiding others; 
supporting another; providing an environment promoting personal development in relation to 
meet future demands; and teaching another” (Nursing Theory, p. 5). For ketogenic diet 
implementation, the role of the nurse is to provide an appropriate avenue for participants to be 
informed, and in doing so, encourage confidence in their care regardless of whether or not they 
choose to participate in the diet change. It is crucial that KD research considers this aspect of 
nursing, as it plays an important role in how data will be collected and to what extent it will be 
accurate.  
Proposal for Further Study 
 Due to the limitations that have been identified by ketogenic diet research, specifically in 
relation to cancer populations, more controlled measures will need to be taken for further study 
in this area of interest. Small sample sizes were a common barrier seen among the studies. In 
particular, participant's inability to continue KD to completion led to attrition, leading to 
inconclusive results. Additionally, insufficient data collection was largely due to the 
incomparability of different cancer types, all of which were studied at different stages and with 
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different biomarkers. With such large inconsistencies in research, it is essential to implement a 
more concise method of study to analyze the specific effects of KD on cancer populations. For 
more accuracy and consistency across data, the subsequent study will address the following 
research question: What are the effects of a ketogenic diet on tumor progression in those with 
glioblastoma?  
While changes will be implemented in the study’s protocols to address these concerns, it 
will still be difficult to fully control all extraneous variables. Participants have a right to 
informed consent, and we cannot blind them to the study’s implementation methods without 
proper education of the risk-benefit analysis of KD. Margins of error related to how involved 
participants will be will also need to be considered. From an ethical standpoint, we cannot force 
a patient to undergo any form of treatment no matter the benefits, and in the case of KD, the 
participant has the final say in whether or not they want to complete the trial. With this in mind, 
the following parameters were designed to carry this research study forward. 
Study Design 
A longitudinal mixed method design will be implemented for this study. Collection of 
data to determine the effects of the ketogenic diet in patients diagnosed with glioblastoma will 
need to take place over a longer period of time. Both qualitative and quantitative data will be 
collected for analysis of holistic effects of KD on cancer patients.  
Specific Aims 
The primary objective of collecting quantitative data will be to precisely measure changes 
in lab values specific to glioblastoma tumor progression during a ketogenic diet and achievement 
of ketogenesis over a six-month period. The secondary objective will be to assess participants’ 
perception of pain and changes in symptoms related to ketogenic diet implementation not 
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associated with other forms of cancer treatment. Qualitative data will additionally be collected to 
explore participant feelings before and after adoption of a ketogenic diet 
Methodology 
A total of ninety participants will be included for KD implementation, and due to the 
conflicting data of different cancer types, this study will only consist of those with glioblastomas. 
Advertising will be administered both physically through paper flyers posted at the UCSF Brain 
Tumor Center in San Francisco and electronically on the News and Blog section of the National 
Brain Tumor Society website. Both advertising campaigns will signify that trial screening is 
open for a two-month window. To meet criteria for the design, participants must be over the age 
of eighteen and have been diagnosed with glioblastoma for at least two weeks. As mentioned 
previously, we cannot force participants to undergo KD for any length of time they do not wish 
to. To decrease the likelihood of this occurrence, an educational session will be held during the 
screening process to inform the participants of the parameters this study will implement. The 
session will include education on what KD is, what specific KD type will be implemented and 
for how long, the potential effects it may have on tumor progression, and the lab work and data 
collection that will be done throughout the study to observe the effects of KD. 
Selection of participants will be conducted as a rolling admission, meaning that all 
applications from participants will be evaluated as they are received rather than altogether once a 
deadline is reached. Participants will be given a three-week period after the study’s educational 
session to decide whether they want to be involved in the study. Should they choose to 
participate, they will partake in a thirty minute interview session before KD implementation to 
discuss feelings regarding their current treatment and what they are hoping to achieve through 
implementation of KD. Another thirty minute interview session will take place at the end of the 
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study asking the same questions now having received KD and whether or not their expectations 
were met, and to what extent. Each interview session will be recorded and analyzed at the 
study’s conclusion to determine significance of KD implementation. 
Data Collection 
The ketogenic diet will be administered over a six month period, and among that time 
four blood tests will additionally be given. The lab work will be to obtain biomarkers related to 
KD effects, with ketogenesis being observed through ketone levels in the blood and glioblastoma 
tumor progression being observed through TKTL1 expression and cfDNA levels in the blood 
respectively. The tests will take place before the KD diet is implemented to obtain participant 
baselines, again two months into the study, then four months in, and finally at the study’s 
conclusion. Additionally, at the two month and four month intervals, a survey will be given to 
determine current feelings on KD’s implementation, symptom assessment using the short form 
of the Brief Pain Inventory (BPI) assessment tool, changes in health and/or quality of life, and 
how confident they feel that they will continue KD to completion. Overall, the total length of 
enrollment, diet implementation, and data collection will take place over the span of two years. 
Data Analysis 
 For analysis of quantitative data, descriptive statistics will be used to describe 
demographic characteristics along with multiple regression, which will examine differences in 
lab values over time. Analysis will additionally be correlation based to determine the relationship 
between KD diet implementation and tumor progression, as measured by the Pearson r 
correlation technique. For analysis of qualitative data, content analysis will be used and 
measured by Colaizzi’s method of data analysis, as described below in Fain’s (2021) sixth 
edition Nursing Research text: 
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1. Describe lived experience under study. 
2. Collect participant descriptions of the lived experience. 
3. Read all participant’s descriptions of the lived experience. 
4. Extract significant statements. 
5. Articulate the meaning of each significant statement. 
6. Aggregate the meanings into clusters of themes. 
7. Write an exhaustive description. 
8. Return to participants for validation of the exhaustive description. 
9. Incorporate any new data revealed during validations into final exhaustive description. 
Conclusion 
While there have been a variety of different research designs and scrutiny regarding the 
ketogenic diet as a cancer therapy, the consensus among the scientific community is this: the 
ketogenic diet, while still in its infancy as a therapeutic cancer intervention, shows promise in its 
effectiveness and potential for long-term benefit. Its influence on tumor progression seems 
notable when paired with additional intervention such as chemo or radiotherapy, and this effect 
extends across a wide variety of cancer types. However, these benefits can only be considered 
with partial strength due to the extensive limitations the study designs faced. Most sample sizes 
were too small to accurately represent KD effects on all cancer populations. Additionally, each 
type of cancer used different methods of measurement that were incomparable with each other. 
Each study also had their own set of parameters that could not be replicated or were not properly 
explained. This lack of homogeneity between cancer types, implementation, and observation 
makes it difficult to reach a joint conclusion. 
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As it stands, KD cannot be properly implemented into clinical practice without further 
research and study analysis. While it has clearly shown promising results in the avenue of 
adjuvant cancer therapy, there are still too many uncertainties that may put patients at risk if 
implemented with the current knowledge we have. That being said, the ideas that KD has 
introduced serve as an exciting opportunity for cancer populations in the pursuit of alternative 
therapy, all with the goal of improving quality of life. More controlled trials will need to be 
conducted to ensure that results are obtained within similar design frameworks, which will build 
validity and reliability that can pave the way for future studies. For nurses and patients alike, 
knowing the effects on different cancers is certainly beneficial, but in the best interest of 
consistent research and data collection, studies should strive for homogeneity in cancer types to 
allow for more authentic variety in KD effects. Tumor progression, body composition, and 
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Appendix A 
Authors/Citation Purpose/Objective of 
Study 
Sample- Population 
of Interest, Sample 
Size 
Study Design Major Findings(s) Strengths Limitations 
Yang, Y.-F., 
Mattamel, P. B., 
Joseph, T., Huang, J., 
Chen, Q., Akinwunmi, 
B. O., Zhang, C. J. P., 
& Ming, W.-K. 
Investigate the 
efficacy of the low 
carb keto diet as an 
adjuvant therapy in 
antitumor treatment 
compared to non-keto 
diets 
  
Establish the role of 
the low carb keto diet 
in cancer treatment 
more clearly 
216 subjects who 
underwent the keto 
diet to completion (4–
24-week range) 
Systematic review and 
meta-analysis 
Results show 
inadequate evidence to 
support beneficial 
effects of LCKD on 
antitumor therapy. Not 
enough studies on the 
mechanism of the keto 
diet, need more 
  
Need more practical 
guidance on use in 
cancer patients such as 
timing of the 
intervention, patient 
age, the severity of the 
disease, and 
nutritional status. 
These factors may 
affect the efficacy of 
KD, but many 
previous studies have 
not addressed this. 
  
Include a bigger 
population to precisely 
compare the KD group 
and the non-KD 
group: same or similar 
types of cancers 
affecting the same 
All studies involved 
human subjects 
  
Excluded trials that 
were non-randomized, 
had no comparison 
group, were non-
human species, were 
conference abstracts, 
book chapters, 
reviews, or other 
forms without detailed 
empirical data and 
have no exposure or 
outcome of interest 
  
Included extensive 
coverage of lipid 
profiles to analyze the 
range of effect of the 
ketogenic diet across 
multiple factions 
All the papers were 
mostly heterogeneous, 
leading to inaccurate 
comparison between 
results and studies 
  
All the included 
papers had different 
types of cancers and 
treatment, made it 
difficult to compare 






responses to LCKDs) 
 
All had small 
populations 
 
Difficult to compare 
all the papers in the 
same sequence 
because each 
measured a different 
type of parameter 
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organ, such as the 
ovaries, uterus, 
prostate, pancreas, 
etc., to have a precise 
comparison group 
Hagihara, K., 
Kajimoto, K., Osaga, 
S., Nagai, N., 
Shimosegawa, E., 
Nakata, H., Saito, H., 
Nakano, M., 
Takeuchi, M., Kanki, 
H., Kagitani-Shimono, 
K., & Kijima, T. 
Study the 
effectiveness of a new 
keto diet regimen in 
patient with different 




effectiveness of the 
keto diet as a support 
therapy and establish 
the degree and 
duration of carb 
restriction more 
clearly in those with 
cancer 
55 gave consent, 37 
took the keto diet 
Patients diagnosed 
with cancer by 
histology or cytology 
and evaluated as stage 
IV on computed 
tomography (CT), 
magnetic resonance 
imaging (MRI), or 
surgery by their 
attending oncologist; 
performance status <2; 
and could take foods 
orally 
15M 22F 
Age 54.8 ± 12.6 
Case series study The effects of the 
ketogenic diet alone 
differ depending on 
the type of cancer, but 
the combined effect of 
the ketogenic diet with 
chemotherapy or 
radiation is promising 
 
Demonstrated that the 
ketogenic diet regimen 
showed stable 
adherence and induced 
functional ketosis with 
high reproducibility 
and was well 





Seems to have an 
effect on long-term 
survival of advanced 
cancer patients  
Evaluated effects of 
the ketogenic over a 




restrictions in cancer 
patients and included 
so in their study 
Lack of homogeneity 
between cancer types 





Lack of control group 
makes it difficult to 
draw meaningful 




Jansen, N., & Walach, 
H. 
Evaluate whether the 
levels of TKTL1 are 
associated with tumor 
status and progression, 
and are affected by a 
ketogenic diet, and 
whether adherence to 
a ketogenic diet is 
associated with a 
better prognosis in 
patients with cancer 
78 subjects diagnosed 
with any form of 
cancer since Jan 2001. 
Diagnosed with any 
type of tumor, or had 
experienced the 
recurrence of a tumor 
or metastasizing 
disease during the 10 
years previous to the 




Results suggest that it 
may be beneficial to 
advise tumor patients 
to adopt a ketogenic 
diet, and that those 
who adhere to it may 
have positive results 
from this type of diet 
Keto diet as a 
complementary 
Present study is the 
first to describe the 
effects of a ketogenic 
diet in patients with 
cancer in primary care 
 
Levels of TKTL1 
were measured 
continuously in the 
patients 
No control condition 
or control group 
matched for important 
predictors 
 
Difficult to preclude 
that the effects 
observed are not 
confounded 
23 
treatment to tumor 
therapy must be 
further studied in 
rigorously controlled 
trials 
Negative link between 
ketogenic diet and 
TKTL1 expression 
In summary, the 
present study has 
demonstrated that a 
ketogenic diet is 
feasible and likely 
beneficial for patients 
with cancer in primary 
care, who have been 
treated for their 
primary cancer, since 
it altered the 
expression of TKTL1, 
a novel and potentially 
useful marker to 
monitor the metabolic 
state of the body 
regarding aerobic 
glycolysis, and to 
evaluate the potential 
progression of non-
end stage tumor 
disease 
 
Results should serve 




Sowerbutts, A. M., & 
Burden, S. 
KDs have the 
potential to influence 
many physiological 
processes. It is 
102 participants 
ranged 34 to 87 years 
old. Brain, rectal, or 
mixed cancer sites 
at an early or 
Systematic review KD is potentially 
feasible and does not 
cause life-threatening 







limited information on 
eligibility of 
participants, and 
details of recruitment 
were only reported in 
24 
therefore important to 
determine whether KD 
adversely affects 
nutritional status in 
individuals with 
cancer. 
Evaluate the current 
evidence on 
anthropometry, 
metabolic changes and 
systemic inflammation 
in individuals with 
cancer who were 
following a KD 
advanced disease 
stage. Intervention 
ranges from 2.4-134.7 
weeks (0.5-31 
months) 
adherence is low and 
possibly linked to a 
limitation in diet 
delivery, as well as a 








evidence in clinical 
practice is still lacking 
cohort studies, 




criteria, had a short 
duration on a KD that 
would not result in 
any potential benefits 
that could be 
attributed to ketosis, 
some studies didn’t 





reliability, had a small 
sample size, 
insufficient statistical 





none of the studies 
assessed the quality of 
evidence using risk 
assessment tools 
25 
Klement, R. J., 
Brehm, N., & 
Sweeney, R. A. 
Summarize data from 
clinical studies that 
have tested KDs along 
with other treatments 
used within medical 
oncology to determine 
the effectiveness of 
KD as a 
complementary 
treatment 
Sample size unknown Systemic review Large beneficial 
effects of KDs on 
body composition for 
both overweight 
patients who benefit 
by losing body weight 
and fat mass while 
maintaining fat-free 
mass and patients at 
risk for excessive 
weight and lean mass 
loss such as head and 





KDs as a supportive 
cancer therapy is 
growing and suggests 
several beneficial 
effects. The largest 
evidence so far is for 
beneficial effects on 
body composition in 
both overweight and 
frail patient 
populations 
Analyzed the effects 
of a ketogenic diet 
across a range of 
different cancers 
Only two of the 




The majority of 
studies included in 
this review suffered 
from different sources 
of bias 
Small sample sizes 
 
Lack of a control 
group, or lack of 
randomization giving 
rise to self-selection, 
allocation, and 
performance bias  
26 
Erickson, N., 
Boscheri, A., Linke, 
B., & Huebner, J. 
Assess clinical 
evidence of isocaloric 





patients with diet 
regime 
330 total patients 
included, but only 177 
followed KD at any 
duration of the study 
 




Systematic review Evidence of benefits 
on tumor development 
and reduction in side 
effects is missing 
 















KD use and discussed 
lack of evidence in 
literature to support 
Low adherence to diet 










Sample survey questionnaire regarding participant involvement in the ketogenic diet. Includes a rating scale ranging from 1-5 
and brief margins to describe personal feelings more in depthly.  
● Have you felt any changes in health since starting KD? 
1 - I feel no different   2 - I feel worse   3 - I feel better 
If you circled 2 or 3 in the previous question, please explain: 
______________________________________________________________ 
● How difficult has it been maintaining KD regularly? 
 1 - Not Difficult   2- Slightly Difficult   3 - Neutral   4 - Difficult   5 - Very Difficult  
Briefly explain why:  
_______________________________________________________________ 
● Have you experienced symptoms separate from your cancer treatment since starting KD? 
 YES                    NO 
If yes, please state them below: 
_______________________________________________________________ 
● How confident do you feel about completing the KD diet? 
1 - Not Confident  2- Slightly Confident  3 - Neutral   4 - Confident  5 - Very Confident 
